KTP (Potassium-titanyl-phosphate) Laser Versus TUR-P (Transurethral Resection of Prostate)
The Effect of KTP Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia (BPH), a Prospective Randomized Study
1 other identifier
interventional
217
1 country
1
Brief Summary
The purpose of this study is to compare safety and efficacy of Green Light PVP (Photoselective Vaporisation of the Prostate) compared to TUR-P.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2011
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
February 21, 2012
CompletedFirst Posted
Study publicly available on registry
December 13, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedNovember 14, 2017
November 1, 2017
4.8 years
February 21, 2012
November 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
IPSS (International Prostate Symptom Score)
symptom
12 months
Secondary Outcomes (8)
DAN-PSS (Danish Prostate Symptom Score)
3, 6 and 12 months
Maximum flow rate (Qmax)
3, 6 and 12 months
Residual urine
3, 6 and 12 months
Length of catheterization
Postoperative recovery
Length of hospital stay
Postoperative recovery
- +3 more secondary outcomes
Study Arms (2)
Green Light Laser
ACTIVE COMPARATORTURP
ACTIVE COMPARATORTransurethral Resection of the Prostate
Interventions
Eligibility Criteria
You may qualify if:
- Men undergoing surgery for BPH
You may not qualify if:
- Previous prostate surgery
- Carcinoma of the prostate
- Neurogenic bladder
- Bladder carcinoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Helsinkilead
- University of Turkucollaborator
- Tampere Universitycollaborator
- South Ostrobothnia Health Care Districtcollaborator
- Oulu University Hospitalcollaborator
Study Sites (1)
Helsinki University Hospital
Helsinki, 00350, Finland
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hannu T Koistinen, M.D.
Helsinki University Central Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Urologist
Study Record Dates
First Submitted
February 21, 2012
First Posted
December 13, 2013
Study Start
January 1, 2011
Primary Completion
October 1, 2015
Study Completion
October 1, 2015
Last Updated
November 14, 2017
Record last verified: 2017-11